文献速递牙周病

糖尿病与非糖尿病牙周炎患者对SRP联合甲硝唑和阿莫西林治疗的临床与微生物学效应:队列研究

Clinical and microbiological effects of scaling and root planing, metronidazole and amoxicillin in the treatment of diabetic and non-diabetic subjects with periodontitis: A cohort study.
PubMed 文献 · J Clin Periodontol · 2018-10-21

本研究纳入29例2型糖尿病和29例非糖尿病重度牙周炎患者,均接受SRP联合甲硝唑400mg每日三次和阿莫西林500mg每日三次治疗14天。1年时两组达到临床终点(≤4个位点PD≥5mm)的比例分别为75.9%和68.9%(p>0.05),但糖尿病组临床附着获得较低且红色和橙色复合菌比例较高(p<0.05)。结论为非糖尿病患者的应答并未优于糖尿病患者。

要点

  • SRP联合甲硝唑和阿莫西林治疗14天,糖尿病与非糖尿病重度牙周炎患者1年临床终点达成率无显著差异。
  • 糖尿病组临床附着获得较低,红色和橙色复合菌比例较高,愈合更依赖牙龈退缩。
  • 非糖尿病患者的临床和微生物学应答并未优于2型糖尿病患者。

核心结论

  • 非糖尿病重度牙周炎患者对SRP+MTZ+AMX治疗的应答并未优于2型糖尿病患者,临床终点达成率和PD改善均无显著差异。
  • 糖尿病患者的微生物学应答稍差,愈合过程更多与牙龈退缩相关。

研究设计与样本

  • 队列研究,纳入29例2型糖尿病和29例非糖尿病重度牙周炎患者。
  • 所有患者接受SRP+甲硝唑400mg每日三次+阿莫西林500mg每日三次,共14天。
  • 基线、治疗后3、6、12个月进行临床和微生物学监测,龈下生物膜样本采用棋盘DNA-DNA杂交分析40种细菌。

主要发现

  • 非糖尿病组和糖尿病组分别有68.9%和75.9%的患者在治疗后1年达到临床终点(≤4个位点PD≥5mm),组间比较p>0.05。
  • 糖尿病组从基线至治疗后1年的平均临床附着获得低于非糖尿病组(p<0.05)。
  • 糖尿病组红色和橙色复合菌的平均比例高于非糖尿病组(p<0.05)。

关键数值与推荐

  • 临床终点定义为≤4个位点探诊深度(PD)≥5mm。
  • 甲硝唑剂量为400mg每日三次,阿莫西林剂量为500mg每日三次,疗程14天。

临床怎么用

  • 对于2型糖尿病合并重度牙周炎患者,SRP联合甲硝唑和阿莫西林治疗可考虑使用,但需预期其微生物学应答可能稍差且愈合更依赖牙龈退缩。
  • 非糖尿病患者使用该联合方案并未显示额外优势,临床决策应综合考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate if non-diabetic subjects with periodontitis respond better than subjects with type 2 diabetes to the treatment protocol of scaling and root planing (SRP), metronidazole (MTZ) and amoxicillin (AMX). MATERIAL AND METHODS: Diabetic and nondiabetic subjects with severe periodontitis received SRP + MTZ (400 mg/thrice a day [TID]) + AMX (500 mg/TID) for 14 days. Subgingival biofilm samples were analyzed by checkerboard DNA-DNA hybridization for 40 bacterial species. Subjects were monitored at baseline, 3, 6 and 12 months post-therapy. RESULTS: Twenty-nine type 2 diabetics and 29 non-diabetic subjects participated of this study. Of the non-diabetics and diabetics, 68.9% and 75.9%, respectively, reached the clinical endpoint for treatment (≤4 sites with probing depth [PD] ≥5 mm) at 1 year post-therapy (p > 0.05). The diabetic group presented lower mean clinical attachment gain from baseline to 1 year post-therapy and higher mean proportions of the red and orange complexes than the non-diabetic group (p < 0.05). CONCLUSIONS: Non-diabetic subjects with severe periodontitis did not respond better than type 2 diabetic subjects to the treatment protocol of SRP + MTZ + AMX, both in terms of achieving the clinical endpoint for treatment and of PD improvement. Diabetic subjects exhibited a slightly worse microbiological response and showed a healing process more associated with gingival recession than the non-diabetics.

来源:J Clin Periodontol,查看原文。版权归原作者所有。

引用

  1. Duarte PM, Feres M, Yassine LLS, et al. Clinical and microbiological effects of scaling and root planing, metronidazole and amoxicillin in the treatment of diabetic and non-diabetic subjects with periodontitis: A cohort study. J Clin Periodontol. 2018. PMID: 30076615. doi:10.1111/jcpe.12994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。